We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
87 hedge funds and large institutions have $152M invested in Crescent Biopharma in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
68% more capital invested
Capital invested by funds: $90.4M → $152M (+$61.4M)
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
56% more call options, than puts
Call options by funds: $475K | Put options by funds: $305K
14% more funds holding
Funds holding: 76 → 87 (+11)
0.02% more ownership
Funds ownership: 0.91% → 0.93% (+0.02%)
Holders
87
Holders Change
+11
Holders Change %
+14.47%
% of All Funds
1.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
33
Reduced
21
Closed
13
Calls
$475K
Puts
$305K
Net Calls
+$170K
Net Calls Change
+$182K
Top Buyers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.35M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$1.15M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$743K |
| 4 |
Renaissance Technologies
New York
|
+$731K |
| 5 |
D.E. Shaw & Co
New York
|
+$583K |
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.65M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$1.42M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$774K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$578K |
| 5 |
Walleye Capital
New York
|
-$407K |
